Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.57 |
| ▸ | DRD2 | P14416 | 7/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179323 | 0.88 | CCNT1 (0.67) | HTR1ADRD2HTR2AHTTCCNT1 | |
| SCHEMBL7884097 | 0.86 | MEN1 (0.55) | HTR1ADRD2HTR2AHTTCCNT1 | |
| SCHEMBL5246497 | 0.86 | OPRM1 (0.59) | HTR1ADRD2HTR2AHTTCCNT1 | |
| SCHEMBL6829563 | 0.86 | KMT2A (0.47) | HTR1ADRD2CCNT1CDK9MEN1 | |
| SCHEMBL6929156 | 0.86 | DRD2 (0.60) | HTR1ADRD2HTR2AHTTCCNT1 | |
| SCHEMBL7886668 | 0.85 | DRD2 (0.54) | HTR1ADRD2HTR2AHTTCCNT1 | |
| SCHEMBL6929163 | 0.85 | DRD2 (0.52) | HTR1ADRD2HTR2AHTTCCNT1 | |
| SCHEMBL614054 | 0.84 | DRD2 (0.53) | HTR1ADRD2HTR2AHTTCCNT1 | |
| SCHEMBL6180652 | 0.82 | PPARG (0.52) | HTR1ADRD2HTR2ACCNT1CDK9 | |
| SCHEMBL2395487 | 0.82 | DRD2 (0.59) | HTR1ADRD2HTR2AHTTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013157-B2 | Synthesis of unsaturated piperidines from piperidones with a silyl reagent | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8013157-B2 | Synthesis of unsaturated piperidines from piperidones with a silyl reagent | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8013157-B2 | Synthesis of unsaturated piperidines from piperidones with a silyl reagent | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20100324292-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | NEELAKANDHA MANI S | 2010-12-23 | — | — | US | disclosed |
| US-20100324292-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | NEELAKANDHA MANI S | 2010-12-23 | — | — | US | disclosed |
| US-20100324292-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | NEELAKANDHA MANI S | 2010-12-23 | — | — | US | disclosed |
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2120572-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | Janssen Pharmaceutica, N.V. (BE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008079255-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079255-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| EP-1851219-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| CN-100345833-C | Modulators of dopamine neurotransmission | CARLSSON RES AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| CN-1255382-C | Novel modulators of dopamine neurotransmission | CARLSSON A RESEARCH AB (SE) | 2006-05-10 | — | — | CN | disclosed |
| CN-1765890-A | Modulators of dopamine neurotransmission | CARLSSON RES AB (SE) | 2006-05-03 | — | — | CN | disclosed |
| US-20040034104-A1 | 2,2-Diphenylbutanamide derivatives and medicines containing the same | SSP CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1325912-A1 | 2,2-DIPHENYLBUTANAMIDE DERIVATIVES AND MEDICINES CONTAINING THE SAME | SSP Co., Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
| CN-1420869-A | Novel modulators of dopamine neurotransmission | CARLSSON A RESEARCH AB (SE) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324292-A1 | SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT | THPO, DHPS, PIR | HTR1A 1595/4885DRD2 109/4885HTR2A 782/4885 |
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | HTR1A 2576/4885DRD2 4152/4885HTR2A 1672/4885 |
| US-20040034104-A1 | 2,2-Diphenylbutanamide derivatives and medicines containing the same | OPRD1, OPRM1, OPRK1 | HTR1A 170/4885DRD2 48/4885HTR2A 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.